WallStreetZenWallStreetZen
Analyst Ranking
Bottom 5%
#4368 out of 4563 analysts
Average Return
-21.68%
Win Rate
17%3 out of 18
Risk vs Reward
Poor
Good

Michael Higgins's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Rhythm Pharmaceuticals IncRYTM
+234.81%$7.70$25.78
2022-02-16 -
2023-02-16
Strong Buy
Rhythm Pharmaceuticals IncRYTM
+79.58%$24.34$43.71
2023-03-01 -
2024-03-01
Strong Buy
Forte Biosciences IncFBRX
+2.71%$0.70$0.72
2024-04-07 -
2024-04-24
Strong Buy

Michael Higgins Analyst Color

Get additional color on Michael Higgins's coverage of popular stocks

Michael Higgins's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Forte Biosciences IncFBRX
1Strong Buy$2.75+281.94%Upgrades
17 days ago
Marinus Pharmaceuticals IncMRNS
1Strong Buy$13.00+802.78%Maintains
8 months ago
Ovid Therapeutics IncOVID
1Strong Buy$7.00+122.22%Reiterates
a year ago
Scynexis IncSCYX
1Strong Buy$15.00N/AReiterates
a year ago
Artelo Biosciences IncARTL
2Strong Buy$60.00N/AReiterates
a year ago
Viridian Therapeutics IncVRDN
2Strong Buy$40.00N/AReiterates
a year ago
Rhythm Pharmaceuticals IncRYTM
3Strong Buy$35.00N/AReiterates
a year ago
Biomx IncPHGE
2Strong Buy$8.00N/AMaintains
2 years ago
4d Pharma PLCLBPS
1Strong Buy$35.00N/AInitiates Coverage On
3 years ago
Astria Therapeutics IncATXS
1Strong Buy$6.00N/AInitiates Coverage On
3 years ago
Novavax IncNVAX
2Strong Sell$105.00N/ADowngrades
4 years ago
Zogenix IncZGNX
1Hold$35.00N/ADowngrades
4 years ago
Virtu Financial IncVIRT
2Strong Buy$29.00N/AUpgrades
5 years ago
Eiger Biopharmaceuticals IncEIGRQ
1Strong Buy$1,050.00N/AInitiates Coverage On
7 years ago
Cempra IncCEMP
2HoldN/AN/ADowngrades
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.